Eric Lefkofsky’s Post

Tempus AI Founder & CEO, Eric Lefkofsky, discusses the transformative role of artificial intelligence in diagnostics on Bloomberg Intelligence's latest episode of the Vanguards of Health Care podcast. Lefkofsky highlights Tempus' innovative platform, linking molecular results with patient data to revolutionize treatment, drug discovery, and clinical trial recruitment. Tune in to learn about their pioneering work in oncology, the evolving landscape of data-driven healthcare, and the future of algorithmic treatment. Listen here: https://lnkd.in/ek_e9jZM #HealthTech #AI #Diagnostics #Founder #Podcast #BloombergIntelligence

“At Pangea, we are trying to broaden the scope of the application of precision medicine. The main problem currently in the field is not that we do not have good enough medicines, we actually have good enough medicines and plenty of them. There have been many approvals of novel and effective drugs in the last 20 years. The key problem is that we do not always know which drug is going to be the most effective for which patients.” Our CEO, Tuvik Beker told Dr. Amar Drawid, Ph.D. on the Life Sciences D’n’A podcast.  At Pangea, we are working to get the right medicines and therapies to the right people. To learn more about how our technology works, how we use data to predict tumor efficacy, our business model, and more watch the full episode here: https://lnkd.in/epeGKUUu CC: Daniel Levine

🌟 AI in Predictive Biomarker Patient Matching: Revolutionizing Personalized Medicine 🌟 The shift towards personalized medicine is reshaping cancer care, offering tailored treatments that improve outcomes and minimize exposure to ineffective therapies. Biomarkers—key molecules indicating biological states—are at the forefront of this revolution. When used effectively, they can significantly boost treatment success rates. However, challenges like data integration, the dynamic nature of biology, and disease heterogeneity have hindered progress. Enter AI. By leveraging machine learning, AI can analyze complex data, track dynamic biomarkers, and predict patient responses, ultimately guiding clinicians toward the most effective treatments. This AI integration promises enhanced patient outcomes, greater clinical trial success, and reduced healthcare costs. At LifeTech Staffing, we're excited to support the growth of AI-driven solutions in precision medicine, connecting top talent with opportunities to make a real impact. Read the full article at https://rb.gy/yxkcin #PersonalizedMedicine #ArtificialIntelligence #Biomarkers #PrecisionMedicine #LifeTechStaffing #HealthcareInnovation

As someone who's deeply passionate about accelerating medical breakthroughs, I constantly see the roadblocks unstructured EHR data creates for clinical trials.    That's why I'm incredibly excited about Science4Tech's CapTrial© solution! This innovative tool leverages GenAI to instantly structure patient data in EHRs, including anamnesis, clinical data, and lab results.   This means: breaking down the data silos for faster insights, reduced data transformation costs and interconnectivity hurdles, as well as improved accuracy by reducing human errors.   I'm so proud of the Science4Tech team for developing this game-changer. We've included a short video showcasing CapTrial@ below. Take a look and let's discuss how we can revolutionise clinical research together!   PS.- Feel free to share your thoughts and experiences with complex EHR data in the comments!

Unlock the future of precision oncology with us on May 14 at 9:00 AM EDT! 🚀 Join our insightful Think Tank on "Strategic Positioning in Precision Health: Competitive Strategies Transforming The Precision Oncology System." Explore the dynamic landscape of precision oncology, where AI, ML, robotics, and big data-driven multi-omics tools are revolutionizing targeted treatments. Our panel of esteemed healthcare experts will delve into: 💡Challenges faced by industry players in precision oncology. 💡Collaborations and partnerships fostering innovation and growth. 💡Impact of reimbursement policies on adoption and scalability. 💡Emerging technologies shaping the future of precision oncology. 💡Unique opportunities and challenges in global expansion. 🔗 Don't miss this opportunity to gain insights and network with leaders in the field. Register now to secure your spot! https://frost.ly/9ws #HealthcareInnovation #AI #ML #Robotics Surbhi Gupta | Unmesh Lal | Alexa Woodward, PhD | Optum | Devmanyu Singh | Roche | Nathan Fowler, MD | BostonGene | Courtney Thornely | Novotech | Sherin George

🤯 Struggling to unlock valuable insights from your EHRs? 80% of healthcare data is unstructured - text, notes, and reports - making it difficult to analyze. CapTrial changes the game. Our platform uses Generative AI to structure, contextualize, and analyze this data. Watch our new video to discover how CapTrial can unlock hidden insights and transform your EHR data into actionable intelligence. Join our upcoming workshop to see a live demo! ️ “From Data Chaos to Cure: Leveraging AI in the Oncology Practice” 📍Meet2Win (Bordeaux) ️ 🗓️ May 16th ⏱️ 4:15 PM CET Can't make it? Contact us today to schedule an online demo! #CapTrial #AIinHealthcare #EHR #DataInsights #Oncology #ClinicalDataManagement #AIClinicalTrials #Innovation #HealthTech #GenAI

HORAIZON and Summa Biotech are pursuing new benchmarks in clinical trial design and patient selection. 🧬💡 Few highlights from AI-ANTENNA: 🔍 Innovative AI Models: Our AI models are now capable of identifying the optimal clinical study population for RNA-based therapies. The precision of these models is poised to transform the landscape of preclinical development by drastically reducing timelines, costs, and risks associated with clinical trials. 🔗 miRNA to Heart Failure Treatment: An important development in our research involves the mapping and pre-selection of genes associated with Ischemic Heart Failure (HF) through miRNA-106b. Our AI platform leverages machine learning to uncover these intricate gene-disease relationships, providing a robust foundation for targeted therapies. 📊 Advanced Analytical Tools: We’ve integrated sophisticated visualization tools like partial dependence and interaction dependence to enhance our understanding of gene-expression and clinical parameters. These tools ensure our models are not only accurate but also interpretable and actionable. 🔬 Network Analysis and AI Models: Our approach includes a comprehensive network analysis of gene interactions, focusing on miRNA-106b and its association with Ischemic HF. By employing KEGG pathway and GO-MF (Gene Ontology - Molecular Function) annotations, our AI models can decipher complex biological networks, identifying key regulatory genes and pathways involved in disease mechanisms. This level of analysis is important for pinpointing potential therapeutic targets and understanding the molecular basis of disease progression. 🌐 Broader Impact: As part of the Dutch AI Coalition’s Health and Care application spectrum, AI ANTENA platform is committed to delivering reliable, transparent, and user-centric solutions. This project utilizes potential of AI to improve healthcare, making it more efficient and patient-focused. Are you interested and would like to learn more - get in touch with our teams! #AI #ClinicalTrials #HealthcareInnovation #Biotech #DigitalHealth #PatientCare #RNAtherapies

🚀  New Regulatory Framework Needed for AI-Based Personalized Therapies 🔬 📈 The landscape of precision oncology is evolving rapidly, with AI technologies now enabling the personalization of drug and cell therapies directly at the patient’s bedside. However, these advancements come with significant regulatory challenges that need urgent attention. 🔬 AI is transforming therapy design, planning, and delivery by optimizing efficacy, reducing toxicity and even personalizing dosing regimes. These developments promise to revolutionize cancer treatment, but the speed of AI advancements is outpacing current regulatory frameworks. 🔍 According to a recent article in Nature, the current regulatory bottlenecks could delay access to life-saving therapies. It's critical that regulatory bodies adapt swiftly to manage the unique risks and benefits of these emerging technologies. This includes creating frameworks that can handle the complex interactions between patient data, AI, and personalized treatments. 🌐 The article highlights that while both the US FDA and EU regulatory bodies have made strides, more innovative approaches are needed to streamline approvals and ensure safe, effective, and timely patient access to AI-enabled therapies. Among the suggestions are enhancing inter-agency communication, adopting flexible frameworks, and investing in regulatory science to keep pace with technological advancements. 🧠 As we move towards an era of AI-driven personalized oncology, we must ensure that our regulatory frameworks are not just reactive but proactively designed to foster innovation while safeguarding patient health. #AI #PrecisionOncology #PersonalizedMedicine #HealthcareInnovation #CancerResearch #HealthcareRegulation Gabrièle Breda Bouchra D. Antoine Bassel Amer -Link below-

🚀 𝐀𝐈 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞: 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐀𝐦𝐢𝐝𝐬𝐭 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬   𝐀𝐈 𝐢𝐬 𝐫𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐢𝐧𝐠 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 with its potential to analyze data at the cellular level to predict cancer drug efficacy and detect breast cancer with unprecedented accuracy.    Yet, the journey to widespread AI adoption is fraught with challenges:   1. 𝐃𝐚𝐭𝐚 𝐐𝐮𝐚𝐥𝐢𝐭𝐲 & 𝐀𝐜𝐜𝐞𝐬𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐲: Ensuring consistent and accurate data across fragmented systems. 2. 𝐈𝐦𝐩𝐥𝐞𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐂𝐨𝐬𝐭𝐬: High investment in infrastructure, compliance, and training. 3. 𝐀𝐜𝐜𝐞𝐩𝐭𝐚𝐧𝐜𝐞: Building trust among healthcare professionals and patients. 4. 𝐏𝐞𝐫𝐟𝐨𝐫𝐦𝐚𝐧𝐜𝐞 𝐄𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧: Developing robust frameworks to assess AI's impact. 5. 𝐓𝐞𝐜𝐡𝐧𝐢𝐜𝐚𝐥 𝐂𝐨𝐦𝐩𝐥𝐞𝐱𝐢𝐭𝐲 & 𝐒𝐤𝐢𝐥𝐥 𝐆𝐚𝐩𝐬: Bridging the expertise gap with specialized training and roles.   Despite these hurdles, the future looks promising. 𝐁𝐲 𝐭𝐚𝐜𝐤𝐥𝐢𝐧𝐠 𝐭𝐡𝐞𝐬𝐞 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐡𝐞𝐚𝐝-𝐨𝐧, 𝐰𝐞 𝐜𝐚𝐧 𝐮𝐧𝐥𝐨𝐜𝐤 𝐀𝐈'𝐬 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐯𝐞 𝐩𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐢𝐧 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞, driving innovation, improving patient care, and enhancing operational efficiency. 💡✨   At 𝑽𝒊𝒗𝒂𝒄𝒕𝒊𝒔, we believe in innovation. Discover our products and services at www.vivactis.ch or contact us at info@vivactis.ch.   #Innovation #DigitalTransformation #HealthcareAI

Now, this is the best use case of #AI. This initiative is driven by someone very near and dear to my heart, who never fails to inspire those around him, Bill Nuti Please follow EverythingALS & click the link below to help #findacure